Cramer's lightning round: Cytokinetics is a very good speculative play

"Mad Money" host Jim Cramer answers callers' stock questions at rapid speed during Tuesday's edition of the lightning round. Subscribe to CNBC PRO for access to investor and analyst insights: https://cnb.cx/2Vtntx6 Cytokinetics: “This is early stage, and here’s what’s interesting about this company: Once again we find these companies that big pharma needs. This is a very good spec. Small molecule therapeutics. The big companies, the Pfizers, love these guys.” LegalZoom.com: “I’ve been watching LZ. It’s going nowhere fast. It’s going nowhere fast. You can’t touch it. It has no backing on Wall Street, none whatsoever.” Matterport: “3D cameras are very, very hot, but they’re too hot for me. I’m going to have to take a pass.” » Subscribe to CNBC TV: https://cnb.cx/SubscribeCNBCtelevision » Subscribe to CNBC: https://cnb.cx/SubscribeCNBC » Subscribe to CNBC Classic: https://cnb.cx/SubscribeCNBCclassic Turn to CNBC TV for the latest stock market news and analysis. From market futures to live price updates CNBC is the leader in business news worldwide. The News with Shepard Smith is CNBC’s daily news podcast providing deep, non-partisan coverage and perspective on the day’s most important stories. Available to listen by 8:30pm ET / 5:30pm PT daily beginning September 30: https://www.cnbc.com/2020/09/29/the-n... Connect with CNBC News Online Get the latest news: http://www.cnbc.com/ Follow CNBC on LinkedIn: https://cnb.cx/LinkedInCNBC Follow CNBC News on Facebook: Follow CNBC News on Twitter: https://cnb.cx/FollowCNBC Follow CNBC News on Instagram: https://cnb.cx/InstagramCNBC https://www.cnbc.com/select/best-cred... #CNBC #CNBCTV